E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
DualityBio will generate and develop ADCs against oncology targets selected by Genentech, using payloads from its DUPAC platform.
imphoenix82
Aurobindo Pharma said the warning letter to Unit I of Eugia Pharma Specialities will have no impact on existing supplies to the US market.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
